Bicycle Therapeutics PLC Sponsored ADR $BCYC Shares Sold by Platinum Investment Management Ltd.

Platinum Investment Management Ltd. decreased its position in shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) by 0.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 285,381 shares of the company’s stock after selling 2,218 shares during the quarter. Platinum Investment Management Ltd. owned 0.41% of Bicycle Therapeutics worth $1,983,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the stock. Armistice Capital LLC lifted its holdings in Bicycle Therapeutics by 21.7% in the first quarter. Armistice Capital LLC now owns 2,672,000 shares of the company’s stock valued at $22,685,000 after acquiring an additional 476,000 shares during the period. Westfield Capital Management Co. LP lifted its holdings in Bicycle Therapeutics by 1.8% in the first quarter. Westfield Capital Management Co. LP now owns 2,657,305 shares of the company’s stock valued at $22,561,000 after acquiring an additional 46,968 shares during the period. Long Focus Capital Management LLC lifted its holdings in Bicycle Therapeutics by 138.2% in the first quarter. Long Focus Capital Management LLC now owns 1,293,753 shares of the company’s stock valued at $10,984,000 after acquiring an additional 750,661 shares during the period. Candriam S.C.A. lifted its holdings in Bicycle Therapeutics by 10.8% in the first quarter. Candriam S.C.A. now owns 1,205,207 shares of the company’s stock valued at $10,232,000 after acquiring an additional 117,331 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in Bicycle Therapeutics by 55.3% in the first quarter. Principal Financial Group Inc. now owns 631,260 shares of the company’s stock valued at $5,359,000 after acquiring an additional 224,790 shares during the period. 86.15% of the stock is owned by institutional investors and hedge funds.

Bicycle Therapeutics Price Performance

Shares of BCYC stock opened at $8.33 on Thursday. The company has a market cap of $577.35 million, a price-to-earnings ratio of -2.37 and a beta of 1.47. The stock has a 50 day simple moving average of $7.45 and a 200-day simple moving average of $7.84. Bicycle Therapeutics PLC Sponsored ADR has a 1-year low of $6.10 and a 1-year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.19). Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%.The firm had revenue of $2.90 million for the quarter, compared to analysts’ expectations of $9.43 million. Analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

BCYC has been the subject of a number of analyst reports. JMP Securities decreased their price target on Bicycle Therapeutics from $22.00 to $10.00 and set a “market outperform” rating for the company in a report on Tuesday, August 12th. Royal Bank Of Canada set a $27.00 price target on Bicycle Therapeutics and gave the company an “outperform” rating in a report on Monday, August 11th. Morgan Stanley reduced their target price on Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 12th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $44.00 target price (down from $48.00) on shares of Bicycle Therapeutics in a research note on Monday, August 11th. Six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $22.22.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.